[go: up one dir, main page]

UY29995A1 - Uso de un antagonista de cb1 para tratar efectos secundarios y síntomas negativos de la esquizofrenia - Google Patents

Uso de un antagonista de cb1 para tratar efectos secundarios y síntomas negativos de la esquizofrenia

Info

Publication number
UY29995A1
UY29995A1 UY29995A UY29995A UY29995A1 UY 29995 A1 UY29995 A1 UY 29995A1 UY 29995 A UY29995 A UY 29995A UY 29995 A UY29995 A UY 29995A UY 29995 A1 UY29995 A1 UY 29995A1
Authority
UY
Uruguay
Prior art keywords
antagonist
chichophrenia
negative symptoms
secondary effects
treat secondary
Prior art date
Application number
UY29995A
Other languages
English (en)
Inventor
Stevens Rachel
Senyah Yaw
Rogacki Nancy
Borowsky Beth
Black Mark
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of UY29995A1 publication Critical patent/UY29995A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención describe y reivindica un método para tratar déficits cognitivos en un paciente que padece esquizofrenia, mediante la administración a dicho paciente de una cantidad terapéuticamente eficaz de un antagonistandel receptor CB1
UY29995A 2005-12-08 2006-12-08 Uso de un antagonista de cb1 para tratar efectos secundarios y síntomas negativos de la esquizofrenia UY29995A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US74843405P 2005-12-08 2005-12-08

Publications (1)

Publication Number Publication Date
UY29995A1 true UY29995A1 (es) 2007-07-31

Family

ID=37964962

Family Applications (1)

Application Number Title Priority Date Filing Date
UY29995A UY29995A1 (es) 2005-12-08 2006-12-08 Uso de un antagonista de cb1 para tratar efectos secundarios y síntomas negativos de la esquizofrenia

Country Status (23)

Country Link
US (1) US20080221078A1 (es)
EP (1) EP1962834A2 (es)
JP (1) JP2009518423A (es)
KR (1) KR20080073737A (es)
CN (1) CN101321523A (es)
AR (1) AR056846A1 (es)
AU (1) AU2006321907A1 (es)
BR (1) BRPI0619541A2 (es)
CA (1) CA2632673A1 (es)
CR (1) CR9957A (es)
DO (1) DOP2006000273A (es)
EC (1) ECSP088505A (es)
IL (1) IL191888A0 (es)
MA (1) MA30090B1 (es)
NO (1) NO20082923L (es)
PE (1) PE20071092A1 (es)
RU (1) RU2008127491A (es)
SV (1) SV2008002929A (es)
TN (1) TNSN08205A1 (es)
TW (1) TW200803839A (es)
UY (1) UY29995A1 (es)
WO (1) WO2007067617A2 (es)
ZA (1) ZA200803924B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200630337A (en) 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
US7906652B2 (en) 2005-11-28 2011-03-15 Merck Sharp & Dohme Corp. Heterocycle-substituted 3-alkyl azetidine derivatives
WO2007110449A1 (en) * 2006-03-29 2007-10-04 Euro-Celtique S.A. Benzenesulfonamide compounds and their use
WO2007118854A1 (en) 2006-04-13 2007-10-25 Euro-Celtique S.A. Benzenesulfonamide compounds and the use thereof
US8791264B2 (en) 2006-04-13 2014-07-29 Purdue Pharma L.P. Benzenesulfonamide compounds and their use as blockers of calcium channels
US8399486B2 (en) 2007-04-09 2013-03-19 Purdue Pharma L.P. Benzenesulfonyl compounds and the use thereof
WO2009040659A2 (en) 2007-09-28 2009-04-02 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
AU2008307572A1 (en) * 2007-10-04 2009-04-09 Merck Sharp & Dohme Corp. Substituted aryl sulfone derivatives as calcium channel blockers
CA2709863A1 (fr) * 2007-12-18 2009-09-03 Sanofi-Aventis Derives d'azetidines, leur preparation et leur application en therapeutique
FR2925051B1 (fr) * 2007-12-18 2010-05-21 Sanofi Aventis Derives d'azetidines,leur preparation et leur application en therapeutique
GB2456183A (en) * 2008-01-04 2009-07-08 Gw Pharma Ltd Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
WO2010079241A1 (es) 2009-01-12 2010-07-15 Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion Uso de antagonistas y/o agonistas inversos de los receptores cb1 para la preparación de medicamentos que incrementen la excitabilidad de las motoneuronas
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
CN107074841B (zh) 2014-08-11 2021-03-26 安吉恩生物医药公司 细胞色素p450抑制剂及其用途
CA2960275A1 (en) * 2014-09-10 2016-03-17 Epizyme, Inc. Smyd inhibitors
US10287282B2 (en) 2014-12-31 2019-05-14 Angion Biomedica Corp. Methods and agents for treating disease
BR112019003732A2 (pt) 2016-08-24 2020-02-18 Prilenia Therapeutics Development Ltd. Aplicação de pridopidina para tratamento de declínio funcional

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6566356B2 (en) * 2000-03-03 2003-05-20 Aventis Pharma S.A. Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation
US6479479B2 (en) * 2000-03-03 2002-11-12 Aventis Pharma S.A. Azetidine derivatives, their preparation and pharmaceutical compositions containing them
US6355631B1 (en) * 2000-03-03 2002-03-12 Aventis Pharma S.A. Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and their preparation
CN1802351A (zh) * 2003-06-11 2006-07-12 麦克公司 被取代的3－烷基和3－链烯基氮杂环丁烷衍生物
RU2006110545A (ru) * 2003-09-02 2007-10-10 Зольвай Фармасьютикалз Гмбх (De) Новое медицинское применение избирательных антагонистов св1-рецептора
WO2006017892A1 (en) * 2004-08-16 2006-02-23 Northern Sydney And Central Coast Area Health Service Methods for improving cognitive functioning
FR2882931B1 (fr) * 2005-03-14 2007-05-18 Sanofi Aventis Sa Compositions pharmaceutiques contenant en association un compose antagoniste des recepteurs aux cannabinoidess et un agent antipsychotique

Also Published As

Publication number Publication date
CR9957A (es) 2008-09-22
CN101321523A (zh) 2008-12-10
TW200803839A (en) 2008-01-16
AU2006321907A1 (en) 2007-06-14
RU2008127491A (ru) 2010-01-20
ZA200803924B (en) 2009-10-28
EP1962834A2 (en) 2008-09-03
US20080221078A1 (en) 2008-09-11
SV2008002929A (es) 2009-12-02
JP2009518423A (ja) 2009-05-07
CA2632673A1 (en) 2007-06-14
TNSN08205A1 (en) 2009-10-30
PE20071092A1 (es) 2007-12-10
AR056846A1 (es) 2007-10-24
DOP2006000273A (es) 2007-10-15
ECSP088505A (es) 2008-08-29
IL191888A0 (en) 2009-08-03
MA30090B1 (fr) 2008-12-01
WO2007067617A2 (en) 2007-06-14
KR20080073737A (ko) 2008-08-11
WO2007067617A3 (en) 2007-11-01
BRPI0619541A2 (pt) 2011-10-04
NO20082923L (no) 2008-09-02

Similar Documents

Publication Publication Date Title
UY29995A1 (es) Uso de un antagonista de cb1 para tratar efectos secundarios y síntomas negativos de la esquizofrenia
MX2010002732A (es) Inhibidores de f1f0-atpasa y metodos relacionados.
MX2010004494A (es) Uso de anticuerpos de trkb para el tratamiento de trastornos respiratorios.
EA200900098A1 (ru) Пептидные соединения для лечения расстройств, связанных с повышенной возбудимостью, и болезней, связанных с дисфункцией ионных каналов
ME01532B (me) Jedinjenja
MA32934B1 (fr) Combinaisons inhibitrices hsp90
MX2010007936A (es) Anticuerpo anti-nr-10 y su uso.
ECSP088619A (es) Combinación de un inhibidor de acetilcolinesterasa y un antagonista de 5-ht6 para el tratamiento de la disfunción cognitiva
BRPI0907135B8 (pt) uso de um anticorpo antagonista anti-cgrp para a prevenção e/ou tratamento de dor de câncer crônica
CY1119800T1 (el) Συνδυασμοι υποδοχεα της 5-ητ4 και αναστολεων ακετυλοχολινεστερασης για τη θεραπεια γνωστικων διαταραχων
MY161656A (en) Therapeutic use of diaminophenothiazines
AR061446A1 (es) Utilizacion de la 1,7 -dimetilxantina para la fabricacion de un medicamento psicoanaleptico no ansiogeno destinado al tratamiento de un trastorno neuropsiquiatrico
BRPI0908635B8 (pt) composto e/ou um sal farmaceuticamente aceitável do mesmo e composição farmacêutica
MY177001A (en) Phenothiazine compounds for treating mild cognitive impairment
MX2011012015A (es) Tratamiento de deterioro cognitivo leve y enfermedad de alzheimer.
MX2009003645A (es) Azaciclilaminas n-sustituidas como antagonistas de histamina-3.
WO2008043052A3 (en) Human antibodies neutralizing human metapneumovirus
MX367811B (es) D-metadona para el tratamiento de síntomas psiquiátricos.
NO20065252L (no) Behandling av forstyrrelser
SG163564A1 (en) Kinin antagonists for treating bladder dysfunction
EA201290764A1 (ru) Способы и композиции для улучшения когнитивной функции
BRPI0506970A (pt) derivados de alfa-aminoamida úteis no tratamento de distúrbios do trato urinário inferior
GT200800167A (es) Inhibidores de pai-1 para tratamiento de afecciones musculares
EA201000433A1 (ru) Лечение вазомоторных симптомов
MA32933B1 (fr) Combinaison d'inhibiteurs de hspo90 et d'herceptine